Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2024 May 4;150(5):231. doi: 10.1007/s00432-024-05753-y

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2024

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 7 — BMAL1 regulates ferroptosis and anticancer agents’ efficacy in vivo. A–B Volumes and weight of subcutaneous tumors in indicated mice. Athymic nude mice were injected subcutaneously with the indicated HL60 cells for 7 days and then treated with RSL3 (30 mg/kg; intraperitoneally, once every other day) at day 7 for 2 weeks. Tumor volumes were calculated once every other day (n = 3 mice per group, *p < 0.05). C–D PTGS2 mRNA and MDA level in isolated tumors at day 14 after treatment were assayed. E The weight of indicated mice and spleen. F–G Volumes and weight of subcutaneous tumors in indicated mice following treatment with venetoclax. Athymic nude mice were injected subcutaneously with the indicated HL60 cells for 7 days and then treated with venetoclax (50 mg/kg; recipient mice were treated with venetoclax (daily by oral gavage) at day 7 for 2 weeks. Tumor volumes were calculated once every other day (n = 5 mice per group, *p < 0.05 versus ctrl + BMAL1^KD group). H–I Volumes and weight of subcutaneous tumors in indicated mice following treatment with dasatinib. Athymic nude mice were injected subcutaneously with the indicated HL60 cells for 7 days and then treated with dasatinib (50 mg/kg; recipient mice were treated with dasatinib (daily by oral gavage) at day 7 for 3 weeks. Tumor volumes were calculated once every three days (n = 4 mice per group, *p < 0.05 versus ctrl + BMAL1^KD group). J–K Volumes and weight of subcutaneous tumors in indicated mice following treatment with sorafenib. Athymic nude mice were injected subcutaneously with the indicated HL60 cells for 7 days and then treated with sorafenib (30 mg/kg; recipient mice were treated with sorafenib (daily by oral gavage) at day 7 for 4 weeks. Tumor volumes were calculated once every three days (n = 3 mice per group, *p < 0.05 versus ctrl + BMAL1^KD group). Data represents the mean ± SD from three to five independent experiments; n.s. (no significance), Statistical significance in (A, F–J) was calculated by two-way ANOVA with Dunnett’s multiple comparison test, by one-way ANOVA with Dunnett’s multiple comparison test for (B–E),and by two-tailed unpaired t test for (G, I, K).*p < 0.05; **p < 0.01; ***p < 0.001. ****p < 0.0001